Screener
Axsome Therapeutics AXSM Royalty — Revenue
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Axsome Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The source filing: Axsome Therapeutics’s 10-Q, filed May 4, 2026.
- Filed
- May 4, 2026, 5:04 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-204274
| Line item | Three months ended March 31, 2026 | Three months ended March 31, 2025 |
|---|---|---|
| Product sales, net | ||
| AUVELITY | $152,696 | $96,231 |
| SUNOSI | 32,631 | 24,127 |
| SYMBRAVO | 4,073 | — |
| Total product sales, net | 189,400 | 120,358 |
| AUVELITY milestone revenue | 500 | — |
| SUNOSI royalty revenue | 1,303 | 1,105 |
| Total revenues | $191,203 | $121,463 |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Axsome Therapeutics's royalty — revenue?
- Axsome Therapeutics (AXSM) reported royalty — revenue of $4.07M in Q1 2026.
- How has Axsome Therapeutics's royalty — revenue changed year-over-year?
- Axsome Therapeutics's royalty — revenue increased by 268.6% year-over-year, from $1.11M to $4.07M.
- What does royalty — revenue mean?
- This metric represents the gross revenue recognized from royalty-based licensing agreements associated with the company's intellectual property portfolio. It reflects the economic value captured from third-party commercialization of licensed assets, excluding any pass-through taxes collected on behalf of government authorities. This revenue stream is a key indicator of the company's ability to monetize its R&D pipeline through strategic partnerships and licensing arrangements.
Ask your AI about Axsome Therapeutics's royalty — revenue.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude